Newsletter | October 27, 2026

10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You

 

Biopharma Supply, Reimagined: Regional, Resilient Manufacturing

 

To ensure robust biomanufacturing operations are independent of global events, supply chains must be flexible and resilient, capable of managing instabilities before shortages occur. This is why we reimagined our supply network through global-local manufacturing strategies. This enables us to ensure a secure, reliable, and consistent supply of essential bioprocessing components and services worldwide for our customers. Read about the details in our white paper.

 
 

TRUSTED BIOPROCESSING PRODUCTS FROM A SITE CLOSER TO YOU

imMEDIAte ADVANTAGE® small-scale custom products Center now open!

The new production facility in Daejeon, South Korea, enables efficient collaboration to meet your custom media, feeds, supplements, and buffers needs. With global site-to-site comparability and consistent quality, our imMEDIAte ADVANTAGE® small-scale custom media services use same-source raw materials as our GMP facilities and provide robust documentation, enabling faster process development and a smooth scale-up.

 

Upgrade your Sampling with NovaSeptum® GO Sterile Sampling Systems

As we expand our production capacity at our Daejeon, South Korea facility, you will benefit from innovative closed sampling systems manufactured closer to you. These systems are supported by the Emprove® Program to streamline qualification and risk assessment. Improve your sampling process now.

 

Discover Our Liquid Buffers and Cleaning-in-Place (CIP) Solutions

Liquid buffers support the stabilization of biologics, CIP solutions the cleaning, storage, and maintenance of resins, consumables, and equipment. Soon manufactured in Daejeon, South Korea, they will come with the Emprove® Dossiers to accelerate your risk assessment. Explore our handbook with information on upstream and downstream raw materials, and CIP solutions!

 

 

Ensuring Supply Chain Security for Biopharma Production

We are expanding our network of regional bioprocessing sites to better serve Asia-Pacific with our new 44,500 m² Bioprocessing Production Center in Daejeon, South Korea. Slated to open in Q4 2026, it will operate alongside our existing sites to provide regional production, and local support. Discover our factory capabilities, sustainability initiatives, and unwavering commitment to quality.